Filipe S, Pereira-Dutra

Dr. Filipe S, Pereira-Dutra

Institute Oswaldo Cruz - FioCruz, Rio de Janeiro, Brazil
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2020 in Science
Verified
Journal Article
Closed access
MBMarta Bosch
Marta Bosch
MSMiguel Sanchez-Alvarez
Miguel Sanchez-Alvarez
AFAlba Fajardo
Alba Fajardo
RKRonan Kapetanovic
Ronan Kapetanovic
BSBernhard Steiner
Bernhard Steiner
APAlbert Pol
Albert Pol
Cells drop a bomb on pathogens: Lipid droplets (LDs) accumulate in cells to serve as lipid storage organelles. They are also an attractive source of nutrients for many pathogens. Bosch et al. show that various proteins involved in innate immunity form complexes on LDs in response to bacterial lipopolysaccharide (see the Perspective by Green). Upon activation, LDs became physically uncoupled from mitochondria, driving a shift in cells from oxidative phosphorylation to aerobic glycolysis. This work highlights the ability of LDs both to kill pathogens directly and to establish a metabolic environment conducive to host defense. This may inform future antimicrobial strategies in the age of antibiotic resistance. Science , this issue p. eaay8085 ; see also p. 294

23 May 2019 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
FPFilipe S, Pereira-Dutra
Filipe S, Pereira-Dutra
LTLivia Teixeira
Livia Teixeira
MCMaria Fernanda de Souza Costa
Maria Fernanda de Souza Costa
PBPatricia Bozza
Patricia Bozza

8 March 2023 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
Suelen Silva Gomes DiasSuelen Silva Gomes Dias
Suelen Silva Gomes Dias
TCTamires Cunha-Fernandes
Tamires Cunha-Fernandes
LSLuciana Souza-Moreira
Luciana Souza-Moreira
VSVinicius Cardoso Soares
Vinicius Cardoso Soares
GLGiselle Barbosa Lima
Giselle Barbosa Lima
PBPatricia Bozza
Patricia Bozza
Zika virus (ZIKV) infection is a global public health concern linked to adult neurological disorders and congenital diseases in newborns. Host lipid metabolism, including lipid droplet (LD) biogenesis, has been associated with viral replication and pathogenesis of different viruses. However, the mechanisms of LD formation and their roles in ZIKV infection in neural cells are still unclear. Here, we demonstrate that ZIKV regulates the expression of pathways associated with lipid metabolism, including the upregulation and activation of lipogenesis-associated transcription factors and decreased expression of lipolysis-associated proteins, leading to significant LD accumulation in human neuroblastoma SH-SY5Y cells and in neural stem cells (NSCs). Pharmacological inhibition of DGAT-1 decreased LD accumulation and ZIKV replication in vitro in human cells and in an in vivo mouse model of infection. In accordance with the role of LDs in the regulation of inflammation and innate immunity, we show that blocking LD formation has major roles in inflammatory cytokine production in the brain. Moreover, we observed that inhibition of DGAT-1 inhibited the weight loss and mortality induced by ZIKV infection in vivo. Our results reveal that LD biogenesis triggered by ZIKV infection is a crucial step for ZIKV replication and pathogenesis in neural cells. Therefore, targeting lipid metabolism and LD biogenesis may represent potential strategies for anti-ZIKV treatment development.

30 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
OCOtávio Chaves
Otávio Chaves
NFNatalia Fintelman-Rodrigues
Natalia Fintelman-Rodrigues
XWXuanting Wang
Xuanting Wang
Carolina SacramentoCarolina Sacramento
Carolina Sacramento
JTJairo Temerozo
Jairo Temerozo
TSThiago Moreno Lopes e Souza
Thiago Moreno Lopes e Souza
Despite the fast development of vaccines, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still circulating and generating variants of concern (VoC) that escape the humoral immune response. In this context, the search for anti-SARS-CoV-2 compounds is still essential. A class of natural polyphenols known as flavonoids, frequently available in fruits and vegetables, is widely explored in the treatment of different diseases and used as a scaffold for the design of novel drugs. Therefore, herein we evaluate seven flavonoids divided into three subclasses, isoflavone (genistein), flavone (apigenin and luteolin) and flavonol (fisetin, kaempferol, myricetin, and quercetin), for COVID-19 treatment using cell-based assays and in silico calculations validated with experimental enzymatic data. The flavonols were better SARS-CoV-2 inhibitors than isoflavone and flavones. The increasing number of hydroxyl groups in ring B of the flavonols kaempferol, quercetin, and myricetin decreased the 50% effective concentration (EC50) value due to their impact on the orientation of the compounds inside the target. Myricetin and fisetin appear to be preferred candidates; they are both anti-inflammatory (decreasing TNF-α levels) and inhibit SARS-CoV-2 mainly by targeting the processability of the main protease (Mpro) in a non-competitive manner, with a potency comparable to the repurposed drug atazanavir. However, fisetin and myricetin might also be considered hits that are amenable to synthetic modification to improve their anti-SARS-CoV-2 profile by inhibiting not only Mpro, but also the 3′–5′ exonuclease (ExoN).

17 February 2022
Verified
Open access
FPFilipe S, Pereira-Dutra
Filipe S, Pereira-Dutra
Coronavirus disease 2019 (COVID-19) is currently a worldwide emergency caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). In observational clinical studies, statins have been identified as beneficial to hospitalized patients with COVID-19. However, experimental evidence of underlying statins protection against SARS-CoV-2 remains elusive. Here we reported for the first-time experimental evidence of the protective effects of simvastatin treatment both in vitro and in vivo. We found that treatment with simvastatin significantly reduced the viral replication and lung damage in vivo, delaying SARS-CoV-2-associated physiopathology and mortality in the K18-hACE2-transgenic mice model. Moreover, simvastatin also downregulated the inflammation triggered by SARS-CoV-2 infection in pulmonary tissue and in human neutrophils, peripheral blood monocytes, and lung epithelial Calu-3 cells in vitro, showing its potential to modulate the inflammatory response both at the site of infection and systemically. Additionally, we also observed that simvastatin affected the course of SARS-CoV-2 infection through displacing ACE2 on cell membrane lipid rafts. In conclusion, our results show that simvastatin exhibits early protective effects on SARS-CoV-2 infection by inhibiting virus cell entry and inflammatory cytokine production, through mechanisms at least in part dependent on lipid rafts disruption.

27 December 2013 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MFMarília D' Avila Farias
Marília D' Avila Farias
POPathise Souto Oliveira
Pathise Souto Oliveira
FPFilipe S, Pereira-Dutra
Filipe S, Pereira-Dutra
TFThiely Jacobsen Fernandes
Thiely Jacobsen Fernandes
CPClaudio Martin Pereira Pereira
Claudio Martin Pereira Pereira
ABAlethéa Gatto Barschak
Alethéa Gatto Barschak